PUR — Pure Biologics SA Cashflow Statement
0.000.00%
- PLN37.22m
- PLN36.08m
- PLN0.10m
Annual cashflow statement for Pure Biologics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | PAS | PAS | PAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.55 | -11.8 | -11.8 | -25.6 | -35.7 |
Depreciation | |||||
Non-Cash Items | 0.18 | 4.1 | 3.01 | 4.76 | 7.42 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 8.97 | 3.19 | -18.2 | 0.955 | -0.772 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 5.33 | -1.35 | -24 | -17.4 | -23.3 |
Capital Expenditures | -0.162 | -0.561 | -0.673 | -5.76 | -0.176 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | 0 | -27.8 | 21.1 | 0.567 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.162 | -0.561 | -28.5 | 15.3 | 0.391 |
Financing Cash Flow Items | -0.143 | -0.349 | -0.227 | -0.329 | -3.11 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 8.55 | -3.05 | 49.7 | -1.88 | 24.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 13.7 | -4.96 | -2.78 | -3.92 | 1.35 |